stock market news, blackberry and aws announce agreement for intelligen 7724060886450207

GLPG - Galapagos NV Stock Trading

Galapagos NV(NASDAQ: GLPG) stock trading, description, contact, officers and directors.

About Galapagos NV

Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti infectives. Galapagos approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target to drug discovery products and services to pharmaceutical and biotech companies.

Stock Information

Galapagos NV Company Name:

GLPG Stock Symbol:

NASDAQ Market:

Galapagos NV Website:

GLPG - Galapagos NV Stock Trading

GLPG GLPG Quote GLPG Short GLPG News GLPG Articles GLPG Message Board

Get GLPG Alerts

News, Short Squeeze, Breakout and More Instantly...

GLPG - Galapagos increases share capital through subscription right exercises

Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 70,925 new ordinary shares on 4 December 2020, for a total capita...
GLPG - Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first dosing in the new MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD). MANGROVE is a random...
GLPG - Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial

Placebo-adjusted improvement in forced vital capacity (FVC) decline of 42mL across treatment groups at 26 weeks Correlation between FVC decline and pulmonary lobar volume change observed, as measured by functional respiratory imaging (FRI) GLPG1205 planned to progress to...